Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Pyxis Oncology, Inc. (PYXS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.22, with a market capitalisation of $286.09M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.03 to $5.55. This page covers its latest market performance, valuation, price trends and company information.
$286.09M | |
$3.41 | |
$19.00 | |
$0.83 | |
$3.33 | |
3.00 | |
1.32M | |
-- | |
$5.55 | |
$1.03 | |
-- | |
-- |
Pyxis Oncology, Inc. (PYXS) is trading at $3.22 in pre-market trading as of 2026-09-16 09:00:00, down 3.30% ($0.11) from the previous close of $3.33
Pre-market trading shows how investors are pricing PYXS before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Pyxis Oncology, Inc. (PYXS) moved from $3.89 to $3.22, representing a decline of 17.22% ($0.67).
The stock traded between $3.07 and $4.15 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.57 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 48.5%
PYXS is currently trading at $3.22, placing it 48.5% of the way from its 52-week low of $1.03 to its 52-week high of $5.55. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 56 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Pyxis Oncology, Inc. (PYXS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.